曲妥珠单抗美坦新与肺动脉高压关联的法国注册与WHO药物警戒分析
本研究结合法国肺动脉高压注册队列与WHO药物警戒数据库的不比例报告分析,评估曲妥珠单抗、曲妥珠单抗美坦新及曲妥珠单抗德鲁替康与肺动脉高压(PH)/肺动脉性肺动脉高压(PAH)的关联。法国注册中识别8例曲妥珠单抗美坦新暴露后新发PAH病例,单用曲妥珠单抗或曲妥珠单抗德鲁替康未见病例;不比例分析中仅曲妥珠单抗美坦新在广义PH与狭义PAH定义下均显示显著信号。
要点
- 曲妥珠单抗美坦新暴露后出现PAH病例,诊断时多伴严重血流动力学损害。
- 药物警戒不比例分析中仅曲妥珠单抗美坦新在广义PH和狭义PAH下均有显著信号。
- 该安全信号需进一步评估并探索其病理生理机制。
核心结论
- 结果提示,与单用曲妥珠单抗相比,更多接受曲妥珠单抗美坦新暴露的患者发生PH。
- 该安全性信号需进一步评估,并需探索其病理生理机制。
研究设计与样本
- 研究分析法国肺动脉高压注册登记(VIGIAPATH项目)中接受曲妥珠单抗、曲妥珠单抗美坦新或曲妥珠单抗德鲁替康治疗的新发PAH病例特征。
- 同期采用WHO药物警戒数据库进行药物警戒不比例报告分析,分别使用广义PH定义与狭义PAH定义。
- 不比例报告信号显著定义为信息成分(IC)的95%可信区间下限大于0。
- 变量以中位数(四分位间距[IQR])表示。
主要发现
- 法国PH注册中识别8例曲妥珠单抗美坦新暴露后新发PAH病例,单用曲妥珠单抗及曲妥珠单抗德鲁替康均无病例。
- 8例均为女性乳腺癌患者,年龄56岁(IQR 49-61岁)。
- 首次暴露至PAH诊断间隔43个月(IQR 4.5-55个月)。
- 诊断时5例为纽约心脏协会功能III/IV级,伴严重血流动力学损害:平均肺动脉压42 mm Hg,心指数2.51 L/min/m2,肺血管阻力9.7 Wood单位。
- 不比例分析中,曲妥珠单抗美坦新在广义PH定义(IC 1.46;0.86-1.95)与狭义PAH定义(IC 1.76;0.83-2.46)下均显示显著信号;曲妥珠单抗仅在广义PH定义下显示显著信号,曲妥珠单抗德鲁替康无显著信号。
关键数值与推荐
- 不比例报告信号显著判定标准:IC的95%可信区间下限大于0。
- 曲妥珠单抗美坦新广义PH定义:IC 1.46(95%CI 0.86-1.95);狭义PAH定义:IC 1.76(95%CI 0.83-2.46)。
- 法国注册8例PAH病例:年龄56岁(IQR 49-61岁);暴露至诊断43个月(IQR 4.5-55个月)。
- 诊断时血流动力学:平均肺动脉压42 mm Hg;心指数2.51 L/min/m2;肺血管阻力9.7 Wood单位;5例NYHA III/IV级。
临床怎么用
- 对接受曲妥珠单抗美坦新治疗的患者,应关注肺动脉高压相关症状并按需评估。
- 识别到曲妥珠单抗美坦新暴露后新发PAH时,可参照本研究特征进行血流动力学评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trastuzumab emtansine has been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH). RESEARCH QUESTION: Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan and the development of PAH? STUDY DESIGN AND METHODS: Characteristics of incident PAH cases treated with trastuzumab, trastuzumab emtansine, or trastuzumab deruxtecan were analyzed from the French Pulmonary Hypertension Registry, the VIGIAPATH program, concurrently with a pharmacovigilance disproportionality analysis using the World Health Organization pharmacovigilance database using a broad definition of pulmonary hypertension (PH) and a narrow definition of PAH. A signal of disproportionate reporting was deemed significant if the lower boundary of the 95% credibility interval of the information component (IC) was superior to 0. The variables were expressed as median (interquartile range [IQR]). RESULTS: In the French PH Registry, we identified 8 incident cases of PAH after trastuzumab emtansine exposure and none with trastuzumab alone or trastuzumab deruxtecan. All cases occurred in female patients (age, 56; IQR, 49-61 years) with breast cancer. The delay between first exposure and PAH diagnosis was 43 months (IQR, 4.5-55). At diagnosis, 5 were in New York Heart Association functional class III/IV with severe hemodynamic impairment (mean pulmonary artery pressure, 42 mm Hg; cardiac index, 2.51 L/min/m2; pulmonary vascular resistance, 9.7 Wood units). Disproportionality analysis showed that only trastuzumab emtansine demonstrated a significant signal of disproportionate reporting using both a broad definition of PH (IC, 1.46; 0.86-1.95) and a narrow definition of PAH (IC, 1.76; 0.83-2.46). Trastuzumab displayed a significant signal using only the broad definition of PH, whereas trastuzumab deruxtecan was not associated with any significant signals of disproportionate reporting. INTERPRETATION: Our results suggest that more patients exposed to trastuzumab emtansine developed PH compared with trastuzumab alone. Further assessment of this safety signal and exploration of pathophysiologic mechanisms is needed.
引用
- Poisson C, Hlavaty A, Favrolt N, et al. Association of Pulmonary Hypertension With Trastuzumab Emtansine: An Analysis of French Pulmonary Hypertension Registry and WHO Pharmacovigilance Database. Chest. 2024. PMID: 39571726. doi:10.1016/j.chest.2024.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。